Radical gastrectomy with D2 lymph node (LN) dissection is the standard surgical procedure for patients with resectable gastric cancer (GC). In the fifteenth edition of the Japanese Classification of Gastric Carcinoma, the 14v LN (LNs along the root of the superior mesenteric vein) was defined as the regional gastric LN. The efficacy of 14v LN dissection during radical distal gastrectomy for lower-third GC remains controversial.
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open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licen ses/by-nc/4.0/ Manuscript source: Unsolicited manuscript INTRODUCTION Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer death worldwide [1] . Radical gastrectomy with D2 lymph node (LN) dissection is the standard surgical procedure for patients with resectable GC [2] [3] [4] [5] [6] [7] [8] . LNs along the root of the superior mesenteric vein are defined as the 14v LNs. In the fifteenth edition of the Japanese Classification of Gastric Carcinoma, the 14v LN was defined as the regional gastric LN [9] . The fifth edition of the Japanese Gastric Cancer Treatment Guidelines states that D2 gastrectomy does not include dissection of the 14v LNs, but D2 (+14v LN) dissection may be beneficial for tumors with apparent metastasis to the No. 6 LN [10, 11] .
The prognosis of patients with 14v LN metastasis is poor [12] [13] [14] . Whether metastasis to the 14v LNs are classified as regional gastric LN metastasis or distant metastasis (M1) remains controversial. An et al [12] found that the 14v LN should be excluded from regional gastric LNs, as the survival of patients with 14v LN metastasis was similar with that of patients with M1 stage disease. The efficacy of prophylactic 14v LN dissection during radical distal gastrectomy for lower-third gastric cancer (LTGC) remains unclear [15, 16] .
Therefore, the aims of the present study were to (A) compare the prognosis of patients with 14v LN metastasis and those with M1 stage disease; (B) evaluate the prognostic significance of adding 14v LN dissection to D2 dissection during radical distal gastrectomy for patients with LTGC; and (C) aid in patient selection for 14v LN dissection. A total of 96 patients with M1 stage disease satisfied the inclusion criteria but were only included for comparing the prognosis of M1 stage patients with 14v LN metastasis. Ultimately, 1004 patients were included in this study. Of these patients, 65 underwent 14v LN dissection [the 14vD (+) group], and the remaining 939 patients did not undergo 14v LN dissection [the 14vD (-) group]. The 14vD (+) group included patients with 14v LN metastasis and those without 14v LN metastasis. After propensity score matching, we included 65 patients in the 14vD (+) group and 65 patients in the 14vD (-) group.
MATERIALS AND METHODS

Patients
There were no predefined indications for adding 14v LN dissection to lymphadenectomy. The decision to perform 14v LN dissection was made at the surgeon's discretion [12] . The TNM stage was defined according to the AJCC guidelines, eighth edition [17] . The extent of lymphadenectomy and LN stations were defined according to the fifteenth edition of the Japanese Classification of Gastric Carcinoma [9] . Eligible patients underwent postoperative chemotherapy with 5-fluorouracil or platinum-based regimens.
The entire study population was followed up via phone and/or outpatient clinic consultation until death or the last follow-up date (December 31, 2017). The Institutional Ethics Committee of China Medical University approved this study. As this was a retrospective study, formal patient consent was not required.
Statistical analysis
All statistical analyses were performed with the Statistical Package for the Social Sciences version 24.0 for Windows (SPSS Inc., Chicago, IL, United States). The chisquared test was used for categorical variables. Overall survival (OS) was analyzed using Kaplan-Meier analysis and compared using the log-rank test. Univariate analysis was performed using the log-rank test. Multivariate analysis for prognostic factors was conducted using the Cox proportional hazard model. The hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the Cox proportional hazard model. A two-tailed P-value < 0.05 was considered statistically significant.
Propensity score matching was used to reduce the effects of selection bias and potential confounding factors. Propensity scores were calculated using a logistic regression model for the following covariates: Age, gender, pT stage, and pN stage. Patients in the 14vD (+) group were matched in a 1:1 ratio with those in the 14vD (-) group using imposed propensity scores with a 0.02 caliper width. We performed propensity score matching using SPSS 24.0 (SPSS Inc., Chicago, IL, United States). Table 1 shows the comparison of the clinicopathological characteristics of the 14vD (+) and the 14vD (-) groups (n = 65 each). Of the 65 patients in the 14vD (+) group, 8 (12.31%) had 14v LN metastasis. There were no significant differences in age, gender, tumor size, histologic grade, pT stage, pN stage, pTNM stage, and postoperative chemotherapy between the 14vD (+) and 14vD (-) groups (all P > 0.05).
RESULTS
Patient characteristics
Patient survival
OS was similar between the 14vD (+) and 14vD (-) groups (HR: 1.01, 95%CI: 0.64-1.58, P = 0.980; Figure 1A ). After stratified analysis, patients with 14v LN metastasis had a significantly shorter OS than the 14vD (+) and 14vD (-) groups (HR: 3.35, 95%CI: 1.51-7.45, P = 0.002; Figure 1B ). The OS of patients with 14v LN metastasis in the 14vD (+) group was similar to that of patients with M1 stage disease (HR: 0.79; 95%CI 0.38-1.65; P = 0.521; Figure 1B ).
Univariate and multivariate survival analyses for the entire population
Univariate analysis indicated that pT stage and pN stage were prognostic factors for OS. Multivariate analysis showed that pT stage and pN stage were independent prognostic factors, while the status of 14v dissection was not a prognostic factor ( Table 2 ).
Subgroup analysis
The forest plot showed that the OS of the 14vD (+) group was similar to that of the 14vD (-) group considering the pathological tumor stage and LN stage ( Figure 2 ). Figure 3 shows the OS according to the status of 14v dissection for each pathological stage. Among patients with pathological stages I, II, and IIIB/IIIC GC, OS was not significantly different between the 14vD (+) and 14vD (-) groups (P = 0.916, P = 0.802, and P = 0.541, respectively); however, the 14vD (+) group had better OS compared with the 14vD (-) group for pathological stage IIIA GC (P = 0.020). On univa5riate analysis, the status of 14v dissection significantly affected the prognosis. Multivariate analysis indicated that the independent prognostic factors for prolonged OS were age < 65 years (P = 0.018) and pT2-3 stage (P = 0.006; Table 3 ).
Univariate and multivariate survival analyses for stage IIIA GC
Frequency of metastasis to each LN station according to the presence of 14v LN metastasis
Tumors with 14v LN metastasis metastasized more often to LN stations 1, 3, 4, 5, 6, 8a, and 11p. This difference was significant for LN stations 1, 6, 8a, and 11p (P < 0.001).
These results may indicate that the presence of 14v LN metastasis can be predicted based on the presence of metastasis to LN stations 1, 6, 8a, and 11p (Figure 4 ). 
DISCUSSION
In the present study, we found that the OS of patients with 14v LN metastasis was comparable to that of patients with M1 stage tumors, similar to previous findings [12] . However, previous studies have also shown that GC patients with 14v LN metastasis without other distant metastasis had a significantly better OS compared to patients with M1 stage GC (P < 0.001) [18, 19] . Given the differences in the results, we cannot directly classify patients with 14v metastasis as having M1 stage GC, and we cannot ignore the potential survival benefits of 14v LN dissection [20, 21] . Therefore, it is important to select appropriate candidates who will benefit from the addition of 14v LN dissection. Some studies supported the addition of 14v LN dissection to D2 gastrectomy for patients with LTGC [19, 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Eom et al [24] showed that 14v LN dissection was an independent prognostic factor for patients with clinical stage III/IV GC in the middle or lower third of the stomach. Liang et al [25] argued that 14v LN dissection might improve the 3-year OS for distal pathological stage IIIB/IIIC GC. Additionally, Chen et al [19] found that adding laparoscopic 14v dissection to laparoscopic-assisted radical distal gastrectomy might improve the OS of cT2-3 patients.
In the present study, we found that, among patients with pathological stage IIIA GC, the 14vD (+) group had better OS compared with the 14vD (-) group (P = 0.020). The TNM stage used in our study was defined according to the AJCC eighth edition, while the sixth edition was used in the study by Eom et al [24] and the seventh edition in the studies by Liang et al [27] and Edge et al [32, 33] . Moreover, our study demonstrated that adding 14v LN dissection had survival benefits for stage IIIA patients, and these results are similar to those obtained by Eom et al [24] and Liang et al [27] .The latter studies evaluated patients with advanced-stage tumors, while the patients in our study had early stage GC. To the best of our knowledge, the present study is the first to evaluate the role of adding 14v LN dissection for patients with different pathological stage GC according to the AJCC eighth edition. We found no effect of adding 14v LN dissection on the OS of patients with pathological stage I and II LTGC. This result could probably be attributed to the rarity of 14v LN metastasis in these diseases. In the studies by An et al [12] and Kong et al [34] [35] [36] , the incidence of 14v LN metastasis was 0% and 2%-3% in stages I and II GC, respectively. Considering the low incidence of 14v LN metastasis in pathological stage I/II LTGC, 14v LN dissection was not recommended for these patients. Moreover, in the current study, 14v LN dissection did not result in better OS of patients with pathological stage IIIB and IIIC LTGC probably because patients with stage IIIB and IIIC GC have more extensive tumor invasion and tend to develop systemic disease.
The 14v LNs are anatomically downstream of the No. 6 LN considering the lymphatic flow for patients with LTGC. In theory, once the No. 6 LN is invaded, there is a high risk of metastasis to the 14v LNs. An et al [12] . reported that metastasis to the No. 6 LN was a useful predictive factor for 14v LN metastasis, with an accuracy rate of 99.0% and false-negative rate of 1.9% [10] . In the present study, all patients with 14v LN metastasis had No. 6 LN metastases. Thus, our study results may indicate that the presence of 14v LN metastasis could be predicted based on the presence of metastasis to LN stations 1, 6, 8a, and 11p.
The present study has some limitations. First, this was a retrospective cohort study, and the clinicopathological features were different between the two groups. 
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